NasdaqCM - Delayed Quote • USD
Akebia Therapeutics, Inc. (AKBA)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 7:57 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.08 | -0.06 | -0.29 | -0.29 |
| Low Estimate | -0.11 | -0.08 | -0.37 | -0.58 |
| High Estimate | -0.05 | -0.03 | -0.21 | 0.17 |
| Year Ago EPS | -0.14 | -0.06 | -0.28 | -0.29 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 46.34M | 49.51M | 189.09M | 171.49M |
| Low Estimate | 40.1M | 45.79M | 188.1M | 125.9M |
| High Estimate | 56M | 54M | 191.06M | 198.6M |
| Year Ago Sales | 40.13M | 56.38M | 194.62M | 189.09M |
| Sales Growth (year/est) | 15.50% | -12.20% | -2.80% | -9.30% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.15 | -0.02 | -0.08 | -0.04 |
| EPS Actual | -0.14 | -0.06 | -0.08 | 0 |
| Difference | 0.01 | -0.04 | 0 | 0.04 |
| Surprise % | 6.70% | -200.00% | 0.00% | 100.00% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.08 | -0.06 | -0.29 | -0.29 |
| 7 Days Ago | -0.08 | -0.06 | -0.29 | -0.29 |
| 30 Days Ago | -0.09 | -0.05 | -0.27 | -0.23 |
| 60 Days Ago | -0.09 | -0.06 | -0.28 | -0.08 |
| 90 Days Ago | -0.09 | -0.06 | -0.29 | -0.05 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | AKBA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 42.90% | -- | -- | 1.60% |
| Next Qtr. | 0.00% | -- | -- | 10.50% |
| Current Year | -3.60% | -- | -- | 5.20% |
| Next Year | 0.00% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.22% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/28/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/15/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 11/17/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/27/2023 |
| Upgrade | HC Wainwright & Co.: Neutral to Buy | 8/28/2023 |
| Reiterates | HC Wainwright & Co.: Neutral to Neutral | 8/11/2023 |
Related Tickers
ARDX Ardelyx, Inc.
6.48
+0.62%
MCRB Seres Therapeutics, Inc.
0.5599
-4.16%
XFOR X4 Pharmaceuticals, Inc.
1.2600
+5.00%
FGEN FibroGen, Inc.
1.1500
-1.71%
ALT Altimmune, Inc.
6.91
+0.29%
CDTX Cidara Therapeutics, Inc.
0.6810
-5.68%
ICU SeaStar Medical Holding Corporation
0.4050
-25.00%
SLS SELLAS Life Sciences Group, Inc.
1.5400
+1.32%
IBRX ImmunityBio, Inc.
5.27
+7.33%
RAPT RAPT Therapeutics, Inc.
7.95
+0.25%